Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BEYAZ vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and drospirenone suppresses gonadotropins (FSH and LH) from the pituitary, inhibiting ovulation, altering cervical mucus, and inducing endometrial changes. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Contraception,Treatment of premenstrual dysphoric disorder (PMDD),Treatment of moderate acne vulgaris in women at least 14 years old who have achieved menarche and desire contraception
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet (drospirenone 3 mg / ethinyl estradiol 0.02 mg) orally once daily for 24 days, followed by 4 days of placebo.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Drospirenone: approximately 30 hours (terminal). Ethinyl estradiol: approximately 13-15 hours (terminal). Steady-state reached within 10 days. Clinical context: once-daily dosing maintains therapeutic levels with minimal accumulation after 3-4 cycles.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via CYP3A4. Ethinyl estradiol undergoes first-pass metabolism in the liver and gut wall. Drospirenone is metabolized via CYP3A4 and also undergoes reduction and sulfation. Metabolites are excreted in urine and feces.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Urine (45-55% as metabolites), feces (30-40% as metabolites), with enterohepatic recirculation of ethinyl estradiol metabolites.
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Drospirenone: 95-97% bound (primarily to albumin). Ethinyl estradiol: approximately 98% bound (mostly to albumin).
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Drospirenone: approximately 3.7 L/kg (suggests moderate tissue distribution). Ethinyl estradiol: approximately 3.6 L/kg (consistent with distribution into body water). Clinical meaning: not extensively stored in tissues.
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: Drospirenone ~76% (relative to IV). Ethinyl estradiol ~55% (due to first-pass metabolism).
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
Contraindicated in patients with renal impairment (creatinine clearance < 50 m L/min). No dose adjustment is recommended for mild impairment (Cr Cl >= 50 m L/min); however, careful monitoring is advised.
No data available for fictional drug ALYACEN 777.
Contraindicated in patients with hepatic impairment (Child-Pugh class A, B, or C). Do not use in acute or chronic liver disease.
No data available for fictional drug ALYACEN 777.
Not indicated for use before menarche. For postmenarchal adolescents, dose is same as adults: one tablet daily following the 24/4 regimen.
No data available for fictional drug ALYACEN 777.
Not indicated for use in postmenopausal women. No specific geriatric dosing is established; use not recommended in this population.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COCs). This risk increases with age, especially in women over 35 years, and with the number of cigarettes smoked. Women who use COCs should be strongly advised not to smoke.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Thrombotic disorders: venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction,Hepatic disease: jaundice, cholestasis, hepatic adenomas,Hypertension: monitor blood pressure,Hyperkalemia: risk in patients with renal impairment, hepatic impairment, or adrenal insufficiency; avoid use with potassium-sparing diuretics or potassium supplements,Gallbladder disease,Carbohydrate and lipid metabolic effects,Headache/migraine,Bleeding irregularities,Depression,Carcinoma: breast and cervical,Ocular lesions: retinal thrombosis
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer,Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenomas or carcinomas (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Renal impairment,Adrenal insufficiency,Hyperkalemia,Use with potassium-sparing diuretics, potassium supplements, or other drugs that increase potassium
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
Grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4, potentially increasing ethinyl estradiol levels and risk of adverse effects. No other specific food interactions are documented, but consider that high potassium foods (e.g., bananas, oranges, spinach) may theoretically contribute to hyperkalemia in susceptible patients, though routine avoidance is not required. Alcohol may increase the risk of liver toxicity, but moderate use is not contraindicated.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
Pregnancy category X. Contraindicated in pregnancy due to known teratogenic effects, including cardiovascular and skeletal anomalies, particularly during first trimester. Use during second and third trimesters is associated with feminization of male fetuses and potential hepatic adenoma. Discontinue immediately if pregnancy occurs.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Excreted in human breast milk. M/P ratio not determined. Can reduce milk production and composition. Use is generally contraindicated during breastfeeding due to potential adverse effects in the infant, including jaundice and fluid retention.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
Not applicable: contraindicated during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased clearance) are irrelevant as drug should be discontinued.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
BEYAZ (drospirenone/ethinyl estradiol) is a combined oral contraceptive (COC) with a 24/4 regimen. The drospirenone component has antimineralocorticoid activity, which can be beneficial for patients with fluid retention or acne. Monitor potassium levels in patients on concomitant medications that increase potassium (e.g., ACE inhibitors, ARBs, NSAIDs). BEYAZ is contraindicated in patients with renal impairment (Cr Cl <30 m L/min) due to risk of hyperkalemia. The 24 active pill regimen provides a longer window of ovulation suppression and may reduce breakthrough bleeding compared to 21-day regimens. Use with caution in patients with a history of depression; drospirenone may affect mood.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one pill at the same time each day, preferably in the evening to minimize nausea.,If you miss a pill, follow the package insert instructions: for one missed pill, take it as soon as remembered; for two or more missed pills, use backup contraception (e.g., condoms) for at least 7 days.,Avoid eating grapefruit or drinking grapefruit juice while taking this medication because it can increase estrogen levels and risk of side effects.,Do not smoke while using BEYAZ, especially if you are over 35, as smoking increases the risk of serious cardiovascular events.,Side effects may include nausea, breast tenderness, headache, and mood changes; report persistent symptoms to your provider.,Seek immediate medical attention if you experience signs of a blood clot: sudden leg swelling, chest pain, shortness of breath, or sudden severe headache.,BEYAZ does not protect against HIV or other sexually transmitted infections; use condoms for protection.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BEYAZ vs ALYACEN 777, answered by our medical review team.
BEYAZ is a Oral Contraceptive that works by Combination of ethinyl estradiol and drospirenone suppresses gonadotropins (FSH and LH) from the pituitary, inhibiting ovulation, altering cervical mucus, and inducing endometrial changes. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BEYAZ and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BEYAZ is: One tablet (drospirenone 3 mg / ethinyl estradiol 0.02 mg) orally once daily for 24 days, followed by 4 days of placebo.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BEYAZ and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BEYAZ is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to known teratogenic effects, including cardiovascular and skeletal anomalies, particularly during first trimester. Use durin. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.